



## Fracture-Related Infection: An Update on Antimicrobial Therapy

Guest Editors:

**Prof. Dr. Willem-Jan  
Metsemakers**

Department of Trauma Surgery,  
University Hospitals Leuven, 3000  
Leuven, Belgium

**Prof. Dr. Werner Zimmerli**

Interdisciplinary Unit of  
Orthopaedic Infections,  
Kantonsspital Baselland, 4410  
Liestal, Switzerland

**Dr. Fintan Moriarty**

AO Research Institute Davos,  
7270 Davos Platz, Switzerland

Deadline for manuscript  
submissions:

**closed (30 June 2022)**

### Message from the Guest Editors

Fracture-related infection (FRI) is one of the most complex problems in orthopedic trauma surgery. It is a serious complication that can have an important impact on patients. In recent decades, the problem of orthopedic device-related infection has gained significant attention; however, this has primarily focused on periprosthetic joint infection (PJI), rather than on FRI. The lack of scientific data, with respect to diagnostic and treatment principles of FRI, has hampered the development of an evidence-based approach for prevention, diagnosis and treatment of this entity. With this Special Issue on FRI, and as members of the *FRI consensus group*, we therefore would like to focus on an aspect of FRI that often has not received sufficient attention in the surgical world, namely, antimicrobial therapy. This issue welcomes submissions within the following scientific fields: basic research, translational research, clinical research and reviews. Key opinion leaders in the field will peer review all manuscripts and consider if they are eligible for publication.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

## Contact Us

---

*Antibiotics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/antibiotics  
antibiotics@mdpi.com  
X@antibioticsmdpi